ClinicalTrials.gg
RecruitingNCT07712848Updated Jul 20, 2026

DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

A Phase 3 interventional study of Arm A (VEN+"2+6"DA) and Arm B (DEC3-VEN) in AML (Acute Myeloid Leukemia), sponsored by The Second Affiliated Hospital of Kunming Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by The Second Affiliated Hospital of Kunming Medical University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
291
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
31st of 433
291 · median 50
Started
2026
with 55 others
Phase 3
54 of 473
25 open now
Primary completion
2026-12
later than 134 of 288 live
Registered
426th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 31st largest by planned enrollment of the 433 interventional ones that give a count, is one of 56 that started in 2026, is one of 54 in phase 3, reaches primary completion later than 134 of the 288 other live ones, and was the 426th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

258 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

Protocol Title: A Prospective, Randomized Controlled Study of Venetoclax Plus 3-Day Decitabine (DEC3-VEN) Versus Venetoclax Plus "2+6" DA Versus "3+7" DA Regimen in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Objective: This is a prospective, open-label, randomized, multicenter, phase II trial designed to compare the efficacy and safety of three induction regimens-Venetoclax plus 3-day Decitabine (DEC3-VEN), Venetoclax plus "2+6" DA, and standard "3+7" DA-in adult patients with newly diagnosed, intensifiable AML.

Study Design: The study employs a prospective, randomized, controlled, multicenter design. A total of 291 eligible patients will be enrolled across approximately 10 centers in China and randomized in a 2:2:1 ratio to the three treatment arms.

Key Eligibility Criteria:

Inclusion: Aged 16-65 with newly diagnosed non-APL AML (excluding favorable CBF-AML), eligible for intensive chemotherapy, ECOG ≤2, and adequate organ function.

Exclusion: Prior AML treatment, secondary AML, active severe infection, significant cardiac comorbidity, or known hypersensitivity to the study drugs.

Interventions:

Induction:

Arm A (VEN+"2+6"DA): Venetoclax (D1-8), Daunorubicin (D2-3), Cytarabine (D2-7).

Arm B (DEC3-VEN): Venetoclax (D1-14), Decitabine (D4-6). FLT3/ITD+ patients add Sorafenib or Gilteritinib (D8-14).

Arm C ("3+7"DA): Daunorubicin (D1-3), Cytarabine (D1-7).

Consolidation (2 cycles):

Arms A/B: Venetoclax + Intermediate-Dose Cytarabine.

Arm C: High-Dose Cytarabine.

Consolidation (Subsequent cycles):

All arms receive multiple cycles of DA or HA regimens.

Maintenance (6-8 cycles):

Arms A/B: Venetoclax + Azacitidine.

Arm C: Azacitidine.

Main Outcome Measures:

Primary Endpoint: Composite Complete Remission Rate (CR + CRi) after induction.

Secondary Endpoints: Overall Survival (OS), CR rate, MRD-negative rate, Relapse-Free Survival (RFS), Event-Free Survival (EFS), and safety.

Keywords: Acute Myeloid Leukemia, Venetoclax, Decitabine, Consolidation Therapy, Maintenance Therapy, Randomized Controlled Trial.

Read the detailed description

This Phase 3, open-label, randomized controlled trial employs a three-arm parallel design to evaluate the optimal integration of venetoclax into intensive chemotherapy for newly diagnosed AML. The study is designed to address the critical unmet need of balancing high remission rates with tolerability in fit adult AML patients.

Scientific Rationale for Treatment Arms:

Arm A (VEN+"2+6" DA) investigates a modified intensive regimen where daunorubicin exposure is limited to 2 days (vs. conventional 3 days) based on prior institutional data suggesting comparable efficacy with reduced cardiotoxicity. Arm B (DEC3-VEN) explores a novel combination of venetoclax with high-dose decitabine (20 mg/m² every 8 hours for 3 days), a regimen developed to enhance hypomethylating effects while limiting myelosuppression duration to approximately 2 weeks through shortened decitabine exposure. Arm C represents the standard "3+7" DA regimen as the reference arm.

Venetoclax Pharmacological Considerations:

The 100→200→400 mg dose ramp-up over 2-3 days is implemented for tumor lysis syndrome (TLS) prophylaxis, with extended dosing through Day 8 (Arm A) or Day 14 (Arm B) based on the pharmacokinetic principle of sustained BCL-2 inhibition. For FLT3-ITD positive patients in Arm B, sorafenib or gilteritinib is added from Day 8 to target dual oncogenic pathways.

Stratification and Randomization:

Randomization employs block randomization with stratification by study center to ensure balance across the 10 participating sites. The 2:2:1 allocation ratio (Arms A:B:C) prioritizes evaluation of the two experimental venetoclax-containing regimens while maintaining adequate power for the standard arm comparison.

MRD Assessment Methodology:

Measurable residual disease is evaluated by multi-parameter flow cytometry (sensitivity 10-⁴) and, where available, NGS-based sequencing to provide complementary sensitivity for treatment response characterization. MRD assessment is performed at remission confirmation and post-consolidation to evaluate depth of response.

Statistical Considerations:

The primary analysis employs a non-inferiority framework comparing the composite CR rate (CR+CRi) of each experimental arm against the standard arm, with a pre-specified non-inferiority margin of -10%. Hierarchical testing controls for multiplicity, prioritizing Arm A followed by Arm B comparisons. An interim analysis for futility is planned after 50% enrollment to preserve resources if either experimental arm shows \<50% response rate.

03

Conditions studied

  • AML (Acute Myeloid Leukemia)

Keywords

  • Acute Myeloid Leukemia
  • Venetoclax
  • Decitabine
  • DA regimen
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Subjects who are suitable for enrollment in this study must meet all of the following criteria:

  1. Except for APL or carrying t(8) that meet the diagnostic criteria (WHO2022 criteria) of the World Health Organization; 21)/(RUNX1::RUNX1TI)、inv(16)(p13.1q22) 、 t(16; 16) (p13.1q22) 、 t(16; 16)/CBFβ::myh11) and other acute myeloid leukemia other than one of the abnormal karyotypes;
  2. Except for acute panmyeloproliferative disease with myelofibrosis and myeloid sarcoma, the World Health Organization AML classification is AML without separate classification;
  3. Newly diagnosed AML patients with male or female, age greater than or equal to 16 years old and less than 65 years old, patients are considered suitable for intensive chemotherapy;
  4. (ECOG) performance status ≤2 at the time of enrollment;
  5. The patient has not received previous AML therapy (except for hydroxyurea and Ara-C\<1.0g/d for reducing tumor compounds);
  6. Pass the following laboratory test indicators (performed within 7 days before treatment):

1) (ALT), alanine aminotransferase (AST) and alkaline phosphatase (ALP) ≤3× (ULN), serum ≤2×ULN; Serum cardiac enzymes \< 2.0× ULN; Unless it is thought to be a leukemic organ involvement.

Creatinine ≥ 30 mL/min, calculated by the formula or measured by 24-hour urine collection;

7. Female subjects of must have a negative pregnancy test result within 72 hours before the start of treatment; Not planning to become pregnant during the study and within 6 months after the last dose of study drug, and negative urine or serum pregnancy test results at screening. Men must use a latex condom during any sexual contact with WOCBP, even if they have had a successful vasectomy, and must agree to avoid childbearing (during treatment and for 6 months after the last dose of study drug).

8. exceeds 2 months;

9. must be signed before the start of all specific study procedures, and the informed consent form must be signed by the patient or his immediate family; Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the legal guardian or the patient's immediate family will sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria are not eligible for this study:

    1. AML with BCR-ABL1; or CML sudden change period;
    2. Treated patients (refers to those who have received induction chemotherapy in the past, regardless of the efficacy);
    3. Subjects with acute panmyelopathy with myelofibrosis or myelosarcoma as defined by WHO 2016;
    4. Secondary leukemia (mainly refers to those who belong to the treatment-related AML subcategory of the World Health Organization (WHO 2016) AML classification and those with a history of pre-stage MDS and/or MPD);
    5. Patients with other hematological diseases (such as hemophilia, myelofibrosis, etc., who are not suitable for inclusion; Those with previous blood picture abnormalities, except for bone marrow examination, MDS and MPD are allowed to be selected);
    6. Pregnant or lactating patients;
    7. Those who are allergic to any drugs involved in this study;
    8. Use of strong or moderate CYP7A inducers within 3 days before the start of study treatment;
    9. Suffering from malignant tumors of other organs (those who need treatment);
    10. Obvious abnormal liver and kidney function, exceeding the enrollment criteria;
    11. Active cardiac disease, defined as one or more of the following:

    <!-- -->

    1. Myocardial infarction less than 6 months from enrollment in the study;
    2. History of arrhythmias requiring medication or severe clinical symptoms;
    3. Uncontrolled or symptomatic congestive heart failure (> Grade 2);
    4. Uncontrolled or symptomatic angina;
    5. below the lower limit of the normal range;

    12. Patients with severe infectious diseases (uncured tuberculosis, pulmonary aspergillosis), known infection with (HIV) or active or C; Subjects with uncontrollable infection.

    13. Subjects with evidence of central nervous system leukemia before treatment;

    14. Subjects with epilepsy, dementia or other abnormal mental states that require medication and cannot understand or follow the protocol;

    15. Restriction of oral drug intake or gastrointestinal absorption;

    16. Those who are not suitable for enrollment in the opinion of the investigator;

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
291 participants (estimated)

Study arms

  • Experimental
    Arm A

    (VEN+"2+6"DA)

    Procedure: Arm A (VEN+"2+6"DA)

  • Experimental
    Arm B

    (DEC3-VEN)

    Procedure: Arm B (DEC3-VEN)

  • Experimental
    Arm C

    ("3+7"DA)

    Procedure: Arm C ("3+7"DA)

Interventions

  • ProcedureArm A (VEN+"2+6"DA)

    Venetoclax (Days 1-8), Daunorubicin (Days 2-3), Cytarabine (Days 2-7)

  • ProcedureArm B (DEC3-VEN)

    Venetoclax (Days 1-14), Decitabine (Days 4-6). FLT3/ITD-positive patients receive additional Sorafenib or Gilteritinib (Days 8-14).

  • ProcedureArm C ("3+7"DA)

    Daunorubicin (Days 1-3), Cytarabine (Days 1-7)

06

What researchers measure

Primary outcomes

  1. Composite Complete Remission Rate after Induction Therapy

    Percentage of patients achieving composite complete remission (CR + CRi) after induction therapy (defined as the first 28-day cycle of treatment). Complete remission (CR) and CR with incomplete hematologic recovery (CRi) are defined according to the European LeukemiaNet (ELN) 2022 criteria. Response is assessed by bone marrow aspiration and biopsy performed at a central laboratory between Day 21 and Day 28 of the induction cycle (or upon count recovery). The measurement unit is the percentage of patients achieving CR or CRi among all randomized patients (intention-to-treat population).

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

Secondary outcomes

  1. Overall Survival (OS)

    Time from randomization to death from any cause (Overall Survival), assessed using the Kaplan-Meier method, with the difference between treatment groups evaluated by the stratified log-rank test. The measurement unit is months.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  2. MRD-negative remission rate

    Percentage of patients achieving measurable residual disease (MRD) negativity, assessed by multiparameter flow cytometry (MFC) with a sensitivity threshold of 0.1% (10-³) in patients who achieved CR/CRi.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Relapse-Free Survival (RFS)

    Time from first documented CR/CRi to confirmed hematologic relapse or death. Relapse defined per ELN 2022 criteria. Assessed by Kaplan-Meier method. Reported as median months with 95% CI.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  4. Event-Free Survival (EFS)

    Event-free survival, defined as the time from randomization to treatment failure (failure to achieve CR/CRi within 6 cycles), confirmed relapse, or death from any cause, whichever occurs first, assessed using the Kaplan-Meier method. The measurement unit is months.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  5. safety profile

    Incidence of treatment-emergent adverse events (TEAEs), assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. The measurement unit is the percentage of patients experiencing each grade of adverse event. Incidence of serious adverse events (SAEs), assessed using the NCI CTCAE version 5.0, with events defined as those leading to death, life-threatening, requiring hospitalization, or causing significant disability.Incidence of grade ≥3 infections, including pneumonia, sepsis, and febrile neutropenia, assessed using the NCI CTCAE version 5.0.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mantzaris I, Goldfinger M, Uriel M, Shastri A, Shah N, Gritsman K, Kornblum NS, Shapiro L, Sica RA, Munoz A, Chambers N, Dhawan A, Verceles JA, Fehn K, Tirone B, Shah L, Clark S, Zhang C, Kim M, Cooper DL, Verma A, Konopleva M, Feldman EJ. Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study. Blood. 2025 Apr 24;145(17):1870-1875. doi: 10.1182/blood.2024026700. PubMed 39919267 ↗
  • Suo X, Fang Z, Wang D, Zhao L, Liu J, Li H, Ma X, Zhang C, Zhao X, Shi R, Wu Y, Jiao Z, Song J, Zhang L, Li L, Zhang S, Lu X, Yuan L, Gao S, Zhang J, Liu K, Zhao X, Bai G, Mi Y. Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial. Hematol Oncol. 2024 Jul;42(4):e3296. doi: 10.1002/hon.3296. No abstract available. PubMed 39041653 ↗
  • Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13. PubMed 30499168 ↗
  • Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2003 Mar 15;101(6):2125-31. doi: 10.1182/blood-2002-06-1714. Epub 2002 Nov 7. PubMed 12424199 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 8 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Jul 20, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07712848
Lead sponsor
The Second Affiliated Hospital of Kunming Medical University
Collaborators
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chines, Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Department of Hematology, Handan Central Hospital, Department of Hematology, The Affiliated Tai'an City Central Hospital of Qingdao University, Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Department of Hematology, The Second Xiangya Hospital, Central South University, Department of Hematology, Guizhou Provincial People's Hospital, People's Hospital of Guangxi Zhuang Autonomous Region, Affiliated Hospital of Qinghai University
Responsible party
ZePing Zhou (DR., The Second Affiliated Hospital of Kunming Medical University) — Principal investigator
First posted
Jul 20, 2026
Start date
Apr 1, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 20, 2026

Study contacts

ZePing Zhou
Contact
zhouzeping@kmmu.edu.cn
+8618788571605
Yaxian Tan
Contact
353964619@qq.com
+8618208821198

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion